HC Wainwright started coverage on shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) in a research report sent to investors on Tuesday morning, Marketbeat reports. The firm issued a buy rating and a $6.50 price target on the biopharmaceutical company's stock.
Several other brokerages have also recently weighed in on NKTR. Piper Sandler began coverage on shares of Nektar Therapeutics in a research note on Monday, November 4th. They set an "overweight" rating and a $7.00 price target for the company. BTIG Research reaffirmed a "buy" rating and set a $4.00 price target on shares of Nektar Therapeutics in a report on Monday, September 30th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $4.10.
Get Our Latest Stock Report on NKTR
Nektar Therapeutics Trading Up 1.0 %
Shares of NKTR stock traded up $0.01 on Tuesday, reaching $1.02. The company had a trading volume of 1,857,284 shares, compared to its average volume of 1,798,594. The stock has a market cap of $188.15 million, a PE ratio of -1.21 and a beta of 0.57. The company has a 50-day moving average of $1.24 and a 200-day moving average of $1.26. Nektar Therapeutics has a 12 month low of $0.46 and a 12 month high of $1.93.
Hedge Funds Weigh In On Nektar Therapeutics
A number of institutional investors have recently added to or reduced their stakes in NKTR. Victory Capital Management Inc. bought a new position in shares of Nektar Therapeutics during the 2nd quarter valued at about $29,000. Valence8 US LP purchased a new position in shares of Nektar Therapeutics in the 3rd quarter valued at approximately $34,000. Intech Investment Management LLC purchased a new position in Nektar Therapeutics during the third quarter valued at $41,000. XTX Topco Ltd bought a new stake in shares of Nektar Therapeutics in the 3rd quarter worth $46,000. Finally, Values First Advisors Inc. bought a new stake in shares of Nektar Therapeutics in the 2nd quarter worth $56,000. 75.88% of the stock is currently owned by institutional investors.
Nektar Therapeutics Company Profile
(
Get Free Report)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
Read More
Before you consider Nektar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.
While Nektar Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
